Understanding the Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

On June 18, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of follicular lymphoma to participate in a virtual workshop to discuss the evolving role of PI3K inhibitors in the treatment of follicular lymphoma. This article summarizes key data about PI3K inhibitors as a therapeutic target as well as insights from stakeholder discussions regarding this topic.

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.